# A Clinical Precision Medicine Approach Reduces Alzheimer's, Dementia and Vascular Risk and Improves Cognition: A Prospective Cohort Study from the Alzheimer's Prevention Clinic at Weill Cornell Medicine and NewYork-Presbyterian

<u>Richard S. Isaacson, MD</u>, <sup>1</sup> Robert Krikorian, PhD,<sup>2</sup> Katherine Hackett, BA,<sup>1</sup> Chiashin Shih, PhD,<sup>3</sup> Jessica Shum, BA,<sup>1</sup> Randy Cohen, MD, MS,<sup>4</sup> Mary Montgomery, RD,<sup>5</sup> Matthew W. Schelke, BA,<sup>1</sup> Roberta Marongiu, PhD,<sup>1</sup> Jeannette Hogg, RD,<sup>1</sup> Robert Kachko, ND,<sup>6</sup> Alon Seifan, MD, MS<sup>7</sup>

(1)Weill Cornell Medicine, New York, NY, USA; (2) University of Cincinnati College of Medicine, Cincinnati, OH, USA; (3) Alzheimer's Prevention Clinic and Research Center, San Juan PR, USA; (4) Crystal Run Healthcare, West Nyack, NY, USA; (5) NewYork-Presbyterian Hospital, New York, NY, USA; (6) Innersource Health, New York, NY, USA; (7) Compass Neurology, Miami, FL, USA

## Weill Cornell Medicine

Corresponding author contact info: rii9004@med.cornell.edu

Biomarkers

Blood

## **– NewYork-Presbyterian**

## Background

The Alzheimer's Prevention Clinic provides direct clinical care to patients who receive evidence-based, individualized early interventions applying principles of pharmacogenomics, nutrigenomics and clinical precision medicine.


### **Objectives**

Our primary outcome measure was change in six AD, dementia, vascular risk scales in response to multi-modal and interventions. Secondary outcome measures include overall and differential effectiveness of interventions on blood biomarkers and cognition (based on genotype and physician & patientreported adherence).

### **Overall Results**

**Risk Scales:** After 6 months, improvements were observed in all risk scales (CAIDE Midlife, p=.046; MLDRI, p=.006; LLDRI, p<.001; MAYO MCI, p<.001; Late-onset AD, p=.001; ANU-ADRI, p<.001).

#### **Change in Risk Scales**



### **Results by Genotype**

**Mediation by genotype:** Stratification by APOE and MTHFR genotypes resulted in variations in response for a host of blood biomarkers and cognitive tests.

#### **Change in Blood Biomarkers & Cognition Mediated by ApoE and MTHFR Status**

	Genotype	otype ApoE					MTHRF C677 1298c								
		E2/E2	E2/E3	E2/E4	E3/E3	E3/E4	E4/E4	C/C A/A	C/C A/C	C/T A/A	C/C C/C	C/T A/C	T/T A/A	T/T A/C	T/T C/C
	n	1	9	3	53	48	12	14	27	19	13	25	22	0	0
♠	Total Cholest.														
	Direct LDL-C														
	HDL-C*														
	Non HDL-C														

### **Study Design & Participants**

This prospective cohort study includes patients with family history of AD and no or minimal cognitive complaints, and preclinical AD or MCI. 168 participants met inclusion criteria (mean age 63 ±14.6, 50.6% female). Using SPSS, paired sample ttests were computed to compare changes in risk scales in subjects with blood biomarker data at baseline and six-months. Changes in blood biomarkers were compared using ANOVA within and across different genotype and adherence groups. Multiple repeated-measured general linear models were computed to compare changes in cognition per genotype and adherence. NIH Toolbox cognitive scores were corrected for age, gender, ethnicity, and education to account for multiple comparisons across groups.


#### Measures


		10100 011	
Clinical assessment	<ul> <li>Visit with neurologist &amp; neurological exam</li> <li>Anthropometrics: vital signs/biometric assessment</li> <li>Laboratory measures: blood biomarkers and genetics</li> </ul>		
Cognitive assessment	<ul> <li>Traditional tests: MMSE; FAS; ANT; Trails B; Boston Naming</li> <li>NIHTB-CB tests: RAVLT Auditory Verbal Learning (Trials 1-3); RAVLT Delayed Recall &amp; Recognition; Dimensional Change Card Sort (DDCS); Flanker Inhibitory Control and Attention; Pattern Comparison Process Speed; Odor Identification; Oral Symbol Digit (OSD); Picture Vocabulary; Oral Reading Recognition</li> </ul>		
Lifestyle & nutritional recommendations	<ul> <li>Preliminary evidence-based multi-modal lifestyle recommendations in accordance with clinical history: nutritional, exercise, cognitive training, social stimulation (Isaacson 2016, Ngandu 2015), stress reduction (Katz, 2016), sleep maintenance (Yaffe, 2014), hyperinsulinemia reduction (Luchsinger, 2014)</li> </ul>	Blood	
	<ul> <li>Recommendations refined based on clinical measures</li> </ul>	improve	
Behavioral assessment	<ul> <li>Adapted MIND-DIET questionnaire (Patient-reported)</li> <li>Rapid Assessment of Physical Activity (RAPA) (Patient-reported)</li> <li>Adherence to recommendations (Physician-reported &amp; Patient-reported)</li> </ul>	months <b>Adhere</b> significa lower a physicia	
Education via AlzU.org	<ul> <li>Evidence-based course on AD prevention</li> <li>Interactive lessons and activities throughout</li> </ul>		
	Alzheimer's Universe	BA	

www.AlzU.org

**Cognition:** Tests of learning, memory, executive function and language improved in participants who completed cognitive assessments at baseline and 6 months (n=120).


#### **Change in Cognitive Measures**





**biomarkers:** A host of blood biomarkers significantly ved in participants who completed labs at baseline and 6 ns (n= 142) see those with \* in table on the right

ence: Higher patient-reported adherence resulted in cant changes in 9 additional blood biomarkers (20) than adherence (11), however there was no difference in ian-reported higher vs. lower adherence groups.



= significant improvement over 6 months, p < .05

## Conclusion

These data suggest a clinical precision medicine approach toward AD prevention reduces AD, dementia and vascular risk and improves cognition. Differential effects were observed based on genotype and adherence. These results are encouraging and warrant further evaluation via randomized trial utilizing AD-specific biomarkers pre vs. post-intervention.

6 MONTH

FOLLOW UP



2 MONTH

• Clinical assessment

- Cognitive assessment
- Behavioral assessment (Patient & Physicianreported)